JP2016512561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512561A5 JP2016512561A5 JP2016501961A JP2016501961A JP2016512561A5 JP 2016512561 A5 JP2016512561 A5 JP 2016512561A5 JP 2016501961 A JP2016501961 A JP 2016501961A JP 2016501961 A JP2016501961 A JP 2016501961A JP 2016512561 A5 JP2016512561 A5 JP 2016512561A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- solvate
- acceptable salt
- naltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 165
- 150000003839 salts Chemical class 0.000 claims description 78
- 239000012453 solvate Substances 0.000 claims description 75
- 208000002193 Pain Diseases 0.000 claims description 62
- 229960003086 naltrexone Drugs 0.000 claims description 54
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 49
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 37
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 37
- 239000005557 antagonist Substances 0.000 claims description 37
- 241000124008 Mammalia Species 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 31
- 239000000651 prodrug Substances 0.000 claims description 21
- 229940002612 prodrug Drugs 0.000 claims description 21
- 239000002552 dosage form Substances 0.000 claims description 20
- SXLHPBDGZHWKSX-UHFFFAOYSA-N 1-(5-amino-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(N)=CC=C1O SXLHPBDGZHWKSX-UHFFFAOYSA-N 0.000 claims description 16
- -1 norbinal tolfimine Chemical compound 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 10
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 9
- 229960005297 nalmefene Drugs 0.000 claims description 9
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 9
- 229960004127 naloxone Drugs 0.000 claims description 9
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 208000004454 Hyperalgesia Diseases 0.000 claims description 8
- 206010053552 allodynia Diseases 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 7
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims description 6
- HITDPRAEYNISJU-UHFFFAOYSA-N amenthoflavone Natural products Oc1ccc(cc1)C2=COc3c(C2=O)c(O)cc(O)c3c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HITDPRAEYNISJU-UHFFFAOYSA-N 0.000 claims description 6
- YUSWMAULDXZHPY-UHFFFAOYSA-N amentoflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 YUSWMAULDXZHPY-UHFFFAOYSA-N 0.000 claims description 6
- HVSKSWBOHPRSBD-UHFFFAOYSA-N amentoflavone Natural products Oc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HVSKSWBOHPRSBD-UHFFFAOYSA-N 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007937 lozenge Substances 0.000 claims description 6
- 229960002921 methylnaltrexone Drugs 0.000 claims description 6
- ZHVWWEYETMPAMX-PCWWUVHHSA-N naltriben Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3OC=25)O)CC1)O)CC1CC1 ZHVWWEYETMPAMX-PCWWUVHHSA-N 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- NQJGJBLOXXIGHL-UHFFFAOYSA-N podocarpusflavone A Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O NQJGJBLOXXIGHL-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- DQCKKXVULJGBQN-OBZTUIKSSA-N (4s,4ar,7as,12br)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@H]5[C@@](C3=4)([C@@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-OBZTUIKSSA-N 0.000 claims description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 5
- 230000002195 synergetic effect Effects 0.000 claims description 5
- 239000011885 synergistic combination Substances 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- RYIDHLJADOKWFM-MAODMQOUSA-N Samidorphan Chemical compound N1([C@@H]2CC3=CC=C(C(=C3[C@@]3([C@]2(CCC(=O)C3)O)CC1)O)C(=O)N)CC1CC1 RYIDHLJADOKWFM-MAODMQOUSA-N 0.000 claims description 4
- 229950006776 samidorphan Drugs 0.000 claims description 4
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 28
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 8
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 8
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 8
- 229960002896 clonidine Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- 229960001680 ibuprofen Drugs 0.000 description 7
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 229960002870 gabapentin Drugs 0.000 description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 4
- 229960001233 pregabalin Drugs 0.000 description 4
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010061979 Genital pain Diseases 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- 241000293861 Scrophularia nodosa Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical group ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
- 229960001894 detomidine Drugs 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 1
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- KDPNLRQZHDJRFU-UHFFFAOYSA-N romifidine Chemical compound FC1=CC=CC(Br)=C1NC1=NCCN1 KDPNLRQZHDJRFU-UHFFFAOYSA-N 0.000 description 1
- 229960005089 romifidine Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/799,287 | 2013-03-13 | ||
| US13/799,287 US20130310412A1 (en) | 2010-06-28 | 2013-03-13 | Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain |
| US13/837,099 | 2013-03-15 | ||
| US13/837,099 US9095548B2 (en) | 2010-04-29 | 2013-03-15 | Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain |
| US13/841,100 | 2013-03-15 | ||
| US13/841,100 US9205081B2 (en) | 2010-04-29 | 2013-03-15 | Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain |
| US13/851,773 | 2013-03-27 | ||
| US13/851,267 US20150111916A9 (en) | 2010-04-29 | 2013-03-27 | Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof |
| US13/851,267 | 2013-03-27 | ||
| US13/851,773 US20150111917A9 (en) | 2010-04-29 | 2013-03-27 | Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain |
| PCT/US2014/025771 WO2014160077A1 (en) | 2013-03-13 | 2014-03-13 | Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512561A JP2016512561A (ja) | 2016-04-28 |
| JP2016512561A5 true JP2016512561A5 (enExample) | 2017-04-13 |
Family
ID=51625328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501961A Pending JP2016512561A (ja) | 2013-03-13 | 2014-03-13 | オピオイド／トール様受容体４アンタゴニスト、そのデキストロエナンチオマーを含む、痛みを軽減するための組成物、及びそのための使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2968293A4 (enExample) |
| JP (1) | JP2016512561A (enExample) |
| AU (1) | AU2014244152A1 (enExample) |
| CA (1) | CA2942641A1 (enExample) |
| WO (1) | WO2014160077A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105449A1 (en) * | 2014-12-22 | 2016-06-30 | Seth Lederman | Compounds for use as pain therapeutics |
| CA2996281C (en) * | 2015-08-31 | 2022-03-08 | Regents Of The University Of Minnesota | Opioid receptor modulators and use thereof |
| EP3511320A4 (en) * | 2016-09-09 | 2020-04-15 | Takeda Pharmaceutical Company Limited | CYCLIC CONNECTION |
| WO2018081792A2 (en) | 2016-10-31 | 2018-05-03 | Allodynic Therapeutics, Llc | Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia |
| WO2020176807A1 (en) | 2019-02-27 | 2020-09-03 | Vanderbilt University | Methods of treating trigeminal nerve pain |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2412409T3 (es) * | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| WO2004071423A2 (en) * | 2003-02-05 | 2004-08-26 | Euro-Celtique S.A. | Methods of administering opioid antagonists and compositions thereof |
| JP2006131545A (ja) * | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | 神経因性疼痛治療剤 |
| GB2447014A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| EP2240022B1 (en) * | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| CA2785056A1 (en) * | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| US20110269727A1 (en) * | 2010-04-29 | 2011-11-03 | Toledano Annette C | Composition to reduce allodynic back pain and related method of use |
| WO2012048294A2 (en) * | 2010-10-07 | 2012-04-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
-
2014
- 2014-03-13 WO PCT/US2014/025771 patent/WO2014160077A1/en not_active Ceased
- 2014-03-13 EP EP14773349.7A patent/EP2968293A4/en not_active Ceased
- 2014-03-13 CA CA2942641A patent/CA2942641A1/en not_active Abandoned
- 2014-03-13 JP JP2016501961A patent/JP2016512561A/ja active Pending
- 2014-03-13 AU AU2014244152A patent/AU2014244152A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512561A5 (enExample) | ||
| ES2526338T3 (es) | Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| RU2008146815A (ru) | Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат | |
| AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
| BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
| CL2013001677A1 (es) | Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia. | |
| CL2007002375A1 (es) | Compuestos derivados de heteroarilo, inhibidores de citocina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, inflamacion, artritis, psoriasis, diabetes, | |
| CL2008000835A1 (es) | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm | |
| WO2007095091A3 (en) | Oral delivery of therapeutic agents using tight junction agonists | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| MA41256B1 (fr) | Dosage spécifique de site d'un inhibiteur de btk | |
| CO6400144A2 (es) | Derivados aminoéster de alcaloides y composición medicinal de los mismos | |
| BR112013009153A2 (pt) | formulação de ligante de fosfato para dosagem única. | |
| JP2008509137A5 (enExample) | ||
| AR069508A1 (es) | Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento | |
| JP2013517304A5 (enExample) | ||
| US20160158222A1 (en) | Combinations of opioid/tlr4 antagonist and a cyclooxygenase (cox) inhibitor for use in the treatment of pain | |
| IL300130A (en) | New combinations for antigen-based therapy | |
| JP2014532728A5 (enExample) | ||
| JP2018513872A5 (enExample) | ||
| CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
| UY33061A (es) | Composiciones para comprimidos desintegrables oralmente de ondansetrón para prevenir náuseas y vómitos | |
| Pan et al. | Synergistic interaction between choline and aspirin against acute inflammation induced by carrageenan and lipopolysaccharide | |
| PE20120956A1 (es) | Composicion farmaceutica que contiene buprenorfina y nalmefeno |